MSB 1.78% $3.86 mesoblast limited

Cell Therapy News/Articles, page-48

  1. 160 Posts.
    lightbulb Created with Sketch. 14
    My 10 cents worth. I am not a statistician. Whilst the prochymal phase 3 trial did not meet its primary end goals there seems to have been significant data suggesting positive responses nonetheless particularly in children. Apparently there were 10% more of the most seriously affected in the prochymal group compared to the control and other design faults that could be improved on. No doubt useful information was learnt for the design of another trial (at least I hope SI thinks so)
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$3.86
Change
-0.070(1.78%)
Mkt cap ! $2.242B
Open High Low Value Volume
$3.96 $3.99 $3.84 $14.98M 3.843M

Buyers (Bids)

No. Vol. Price($)
9 25055 $3.86
 

Sellers (Offers)

Price($) Vol. No.
$3.89 6598 3
View Market Depth
Last trade - 16.10pm 02/06/2020 (20 minute delay) ?
(live)
Last
$3.86
  Change
-0.070 ( 2.23 %)
Open High Low Volume
$3.98 $3.98 $3.85 1023942
Last updated 15.59pm 02/06/2020 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.